Twist Bioscience Gives Impressive Presentation at the Virtual American Society for Human Genetics 2020 Annual Conference

A recent article in BioSpace highlighted presentations by Twist Bioscience, a rapidly growing genomic and synthetic biology company. Twist presented its product line at the virtual 2020 Annual Meeting of…

Continue Reading Twist Bioscience Gives Impressive Presentation at the Virtual American Society for Human Genetics 2020 Annual Conference
New Combination for HRD-Positive Ovarian Cancer Gets EU Approval
source: pixabay.com

New Combination for HRD-Positive Ovarian Cancer Gets EU Approval

According to a story from Cancer Network, the European Commission has recently approved a two-part combination treatment for advanced, homologous recombination deficiency (HRD)-positive ovarian cancer. This first-line maintenance treatment consists…

Continue Reading New Combination for HRD-Positive Ovarian Cancer Gets EU Approval
Astellas Pharma Provides Help, Guidance, and Hope for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Andrew Krivoshik, M.D., Ph.D., was promoted to senior vice president and Oncology Therapeutic Area Head on April 1, 2019

Astellas Pharma Provides Help, Guidance, and Hope for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Astellas Pharma, headquartered in Northbrook, Illinois presents its Be R/Ready program to promote patient-physician communication as well as other valuable and informative resources. Their program centers around patients with relapsed…

Continue Reading Astellas Pharma Provides Help, Guidance, and Hope for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Recurrence-Free Survival in High-Risk Stage III Melanoma With Pembrolizumab Confirmed by Long Term Follow-up
source: pixabay.com

Recurrence-Free Survival in High-Risk Stage III Melanoma With Pembrolizumab Confirmed by Long Term Follow-up

  According to a recent report in the Journal of Clinical Oncology, over one thousand patients with high-risk stage III melanoma were included in the Keynote-054 clinical trial (NCT02362594). The…

Continue Reading Recurrence-Free Survival in High-Risk Stage III Melanoma With Pembrolizumab Confirmed by Long Term Follow-up
Study Identifies Predictive Tools to Shorten Active Surveillance Required in Prostate Cancer
Source: Pixabay

Study Identifies Predictive Tools to Shorten Active Surveillance Required in Prostate Cancer

PracticeUpdate recently published an article relating to a study with the primary goal of lightening the burden that many males experience regarding long-term prostate surveillance. Active surveillance has been preferred…

Continue Reading Study Identifies Predictive Tools to Shorten Active Surveillance Required in Prostate Cancer
Genomic Testing for Rare Cancers
source: pixabay.com

Genomic Testing for Rare Cancers

According to an article from BioSpace, the TargetCancer Foundation has began enrolling patients in their TRACK study. This study is intended to provide rare cancer patients with individualized treatment options…

Continue Reading Genomic Testing for Rare Cancers
MN-166 (Ibudilast) Shows Promise for CIPN
Source: Pixabay.com

MN-166 (Ibudilast) Shows Promise for CIPN

  Early last week, biopharmaceutical company MediciNova Inc. ("MediciNova") announced promising results for their therapeutic candidate MN-166 (ibudilast). The company, which published in the findings in Cancer Chemotherapy and Pharmacology, explored…

Continue Reading MN-166 (Ibudilast) Shows Promise for CIPN
First Patient Dosed in Phase 2 Trial to Evaluate AU-011 for Choroidal Melanoma
cocoparisienne / Pixabay

First Patient Dosed in Phase 2 Trial to Evaluate AU-011 for Choroidal Melanoma

  Recently, clinical-stage biopharmaceutical company Aura Biosciences announced a Phase 2 clinical trial to determine the safety, efficacy, and tolerability of AU-011 for patients with choroidal melanoma. Currently, Aura Biosciences…

Continue Reading First Patient Dosed in Phase 2 Trial to Evaluate AU-011 for Choroidal Melanoma
An Experimental Diagnostic for Neuroblastoma has Earned Rare Pediatric Disease Designation
source: pixabay.com

An Experimental Diagnostic for Neuroblastoma has Earned Rare Pediatric Disease Designation

According to a story from BioSpace, the radiopharmaceutical company Clarity Pharmaceuticals, Inc. has announced recently that its experimental diagnostic 64Cu-SARTATE™ has earned Rare Pediatric Disease designation from the US Food…

Continue Reading An Experimental Diagnostic for Neuroblastoma has Earned Rare Pediatric Disease Designation
Onureg Approved for Continuous AML Treatment
https://pixabay.com/en/skeleton-hand-bones-anatomy-joint-778069/

Onureg Approved for Continuous AML Treatment

Earlier this week, the FDA approved oral azacitidine (Onureg) for patients with acute myeloid leukemia (AML). According to the ASCO Post, Onureg continuously treats adult patients who previously achieved remission.…

Continue Reading Onureg Approved for Continuous AML Treatment